Bayer Healthcare Pharmaceuticals Plant, Snohomish County, Washington State

closed

Berlex Laboratories LLC based in Bothell, Washington was the US subsidiary of the German pharmaceutical company Schering 2004 New biopharmaceutical facility Snohomish County, Washington State $60m 2007 Leukine Bayer Healthcare Pharmaceuticals, Schering AG Skanska USA Bayer Healthcare Pharmaceuticals, Schering AG Berlex Laboratories LLC based in Bothell, Washington was the US subsidiary of the German pharmaceutical company Schering AG. In 2004 Berlex and Schering decided to construct a new 95,000ft² (8,361m²) biopharmaceutical facility in north west Washington State in the Seattle metropolitan area (Lynnwood, Snohomish County). In mid-2006, Schering was acquired by Bayer Pharmaceuticals. Subsequently, on 4 April 2007, Berlex changed its name to Bayer Healthcare Pharmaceuticals. In August 2004 the company purchased a 16 acre (6.4ha) site in the Northpointe Corporate Center (owned by Opus Northwest LLC) for $10m. Northpointe Center is located 17 miles (27km) north of Seattle. The centre provides infrastructure with robust fibre optic and telecommunication capacity to handle engineering, biomedical and high tech companies. Construction of the $60m plant was completed in 2007. The facility has joined a growing number of biopharmaceutical facilities in the area. It was then the biggest new facility in biopharma in Washington State. Snohomish County has attracted more than 30 biotech operations; collectively, they account for about 25% of Washington State’s total biotech jobs. The facility is in early licensure for the production of Leukine (sargramostim). Leukine is a haematopoietic growth factor that stimulates neutrophils, monocyte/macrophages and dendritic cells, and is used in the stimulation of the immune system following prolonged treatment with chemotherapy. It is also used in the treatment of patients following bone marrow transplantation. Leukine (sargriamostim) was first approved in 1991 by the Food and Drug Administration (FDA). On 31 May 2009, Bayer Healthcare announced a strategic alliance with Genzyme Corporation. Under the terms of the alliance Genzyme will acquire the Leukine manufacturing facility after it obtains the FDA licence. In addition, Bayer will license its haematological oncology products to Genzyme and also transfer its portfolio of haematological oncology products. Bayer is also seeking approval for the drug’s use in treating Crohn’s disease, a chronic illness that causes digestive tractirritation. Snohomish County plant construction and manufacturing Bayer Healthcare has 200 employees based in Seattle and Bothell at the former Immunex Corporation plant, which passed into the company in 2002 when Schering spent $380m in purchasing the Leukine operations belonging to Immunex to diversify its US healthcare business. When Immunex merged with Amgen it spun its proven Leukine product to Berlex for full production. Berlex wanted to stay in the geographical area to make use of the personnel it already had with expertise in the manufacture of Leukine at the Puget Sound plant. Snohomish County Economic Development Council gave advice and incentives to Berlex for bringing the plant to Snohomish County. The new plant has increased the US production of Leukine. Berlex had carried out Phase III clinical studies to evaluate Leukine as a Crohn’s and arthritis treatment. However, in July 2006, Schering announced that the results of the clinical trial were insufficient. The plant may also be used for contract manufacture of other biopharmaceuticals. The complex will consist of two manufacturing buildings, a power generation building and an administration block. The main contractor for the project is Skanska USA Building of Seattle. Icon Genetics Icon Genetics AG has entered into a collaborative agreement with Berlex to evaluate the expression levels and quality of selected Berlex preclinical pharmaceutical proteins when expressed in transgenic plants using Icon’s proprietary magnICON biomanufacturing platform technology. This provides a method for producing therapeutic and other high-value recombinant proteins using non-GMO (genetically modified organisms) non-food plants as a production host. The technology provides for the extraordinary amplification level of the gene of interest and simultaneous shut-off of the other biosynthetic processes in the cell, resulting in the highest theoretically possible yield and relative yield of a recombinant protein in a plant cell. The magnICON technology also allows for rapid production in a timescale of only weeks of gram quantities of recombinant proteins necessary for clinical trials, thus eliminating the major R&D bottleneck. This technology may well be used in the new Berlex plant. Get industry leading news, data and analysis delivered to your inbox Give your business an edge with our leading industry insights.

High